Australia grants first approval worldwide to Pharmaxis' cystic fibrosis therapy
This article was originally published in Scrip
Executive Summary
Pharmaxis has received the first regulatory clearance worldwide for its cystic fibrosis (CF) therapy Bronchitol, in its home market of Australia.